PLOS ONE:肺癌患者的氧化应激与脂质代谢的血清标志物改变有关

2019-04-13 海北 MedSci原创

在肺癌(LC)中,人们广泛观察到氧化还原平衡的改变,并且是疾病以及与吸烟共同发生的结果。研究人员之前已经证明,代谢紊乱,如微量元素状态和碳水化合物代谢改变,与氧化还原状态有关。

肺癌LC)中,人们广泛观察到氧化还原平衡的改变,并且是疾病以及与吸烟共同发生的结果。研究人员之前已经证明,代谢紊乱,如微量元素状态和碳水化合物代谢改变,与氧化还原状态有关。

最近进行的一项研究的目的就是评估LC患者血清脂质代谢参数与氧化还原平衡之间的关系。

92LC患者和82名对照受试者(CS)中,研究人员测定了脂质代谢的血清参数,即总胆固醇TC),HDL胆固醇HDL-C),LDL胆固醇(LDL-C),甘油三酯(TG),TCHDL-C比率,非HDL-C,载脂蛋白A1 Apo-A1),载脂蛋白BApo-B)和Apo-BApo-A1比率,以及全身氧化还原状态,即总抗氧化状态(TAS),总氧化剂状态(TOS),氧化应激指数(OSI),维生素EVE),维生素CVC),丙二醛(MDA),共轭二烯(CD)和4-羟基壬烯醛(4-HNE)。

CS相比,LC女性的T-CLDL-C显着降低,TG更高,而LC患者的HDL-CApo-A1Apo-B显着降低,无论性别如何。 LC男性的全身总氧化还原平衡发生改变,例如TAS较低,OSICS男性高。 LC女性的VC较低,但LC患者的VE降低,无论性别如何。

此外,研究人员观察到,有较高的4-HNECD表达的LC患者中脂质过氧化更高。全身氧化还原紊乱与血清脂质改变相关:TOSOSIT-CHDL-C比率和Apo-BApo-A1比率呈正相关,与HDL-C呈负相关。脂质过氧化CDMDA的参数与反映脂质紊乱的变量显着相关。一般超重/肥胖,腹部肥胖,高甘油三酯血症和非吸烟状态加强了观察到的相关性。

总之,与脂质改变相关的参数与LC患者中的氧化应激相关。脂质参数的最大贡献显示为T-CHDL-C比率,HDL-CApo-BApo-A1比率,而OSIVE为氧化还原状态的最大贡献者。超重,肥胖,高甘油三酯血症和非吸烟状态加剧了这些关系。


原始出处:

Zabłocka-Słowińska K et al. Oxidative stress in lung cancer patients is associated with altered serum markers of lipid metabolism. PLOS ONE, 2019; doi: 10.1371/journal.pone.0215246. eCollection 2019.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990681, encodeId=48c71990681af, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Jan 12 21:52:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790337, encodeId=e5631e90337ac, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 25 10:52:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704073, encodeId=adfd1e0407341, content=<a href='/topic/show?id=f407894051e' target=_blank style='color:#2F92EE;'>#血清标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89405, encryptionId=f407894051e, topicName=血清标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de7930650164, createdName=jichang, createdTime=Thu Nov 07 09:52:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841381, encodeId=6e92184138146, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 29 18:52:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353396, encodeId=31e4135339681, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445278, encodeId=776c14452e8a7, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990681, encodeId=48c71990681af, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Jan 12 21:52:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790337, encodeId=e5631e90337ac, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 25 10:52:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704073, encodeId=adfd1e0407341, content=<a href='/topic/show?id=f407894051e' target=_blank style='color:#2F92EE;'>#血清标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89405, encryptionId=f407894051e, topicName=血清标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de7930650164, createdName=jichang, createdTime=Thu Nov 07 09:52:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841381, encodeId=6e92184138146, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 29 18:52:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353396, encodeId=31e4135339681, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445278, encodeId=776c14452e8a7, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990681, encodeId=48c71990681af, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Jan 12 21:52:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790337, encodeId=e5631e90337ac, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 25 10:52:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704073, encodeId=adfd1e0407341, content=<a href='/topic/show?id=f407894051e' target=_blank style='color:#2F92EE;'>#血清标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89405, encryptionId=f407894051e, topicName=血清标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de7930650164, createdName=jichang, createdTime=Thu Nov 07 09:52:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841381, encodeId=6e92184138146, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 29 18:52:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353396, encodeId=31e4135339681, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445278, encodeId=776c14452e8a7, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1990681, encodeId=48c71990681af, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Jan 12 21:52:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790337, encodeId=e5631e90337ac, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 25 10:52:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704073, encodeId=adfd1e0407341, content=<a href='/topic/show?id=f407894051e' target=_blank style='color:#2F92EE;'>#血清标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89405, encryptionId=f407894051e, topicName=血清标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de7930650164, createdName=jichang, createdTime=Thu Nov 07 09:52:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841381, encodeId=6e92184138146, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 29 18:52:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353396, encodeId=31e4135339681, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445278, encodeId=776c14452e8a7, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1990681, encodeId=48c71990681af, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Jan 12 21:52:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790337, encodeId=e5631e90337ac, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 25 10:52:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704073, encodeId=adfd1e0407341, content=<a href='/topic/show?id=f407894051e' target=_blank style='color:#2F92EE;'>#血清标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89405, encryptionId=f407894051e, topicName=血清标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de7930650164, createdName=jichang, createdTime=Thu Nov 07 09:52:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841381, encodeId=6e92184138146, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 29 18:52:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353396, encodeId=31e4135339681, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445278, encodeId=776c14452e8a7, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1990681, encodeId=48c71990681af, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Jan 12 21:52:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790337, encodeId=e5631e90337ac, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 25 10:52:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704073, encodeId=adfd1e0407341, content=<a href='/topic/show?id=f407894051e' target=_blank style='color:#2F92EE;'>#血清标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89405, encryptionId=f407894051e, topicName=血清标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de7930650164, createdName=jichang, createdTime=Thu Nov 07 09:52:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841381, encodeId=6e92184138146, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 29 18:52:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353396, encodeId=31e4135339681, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445278, encodeId=776c14452e8a7, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Apr 15 12:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]

相关资讯

Opdivo肺癌长期疗效结果公布,4年总生存达到14%

日前,百时美施贵宝(BMS)在美国亚特兰大举行的AACR年会上公布了该公司的抗PD-1重磅药Opdivo(nivolumab),作为2线疗法治疗非小细胞肺癌(NSCLC)患者的长期生存结果。汇集了CheckMate-017, -057, -063, 和-003四个3期临床试验中总计664名患者的试验结果表明,接受Opdivo治疗的患者在4年之后,总生存率(OS)达到14%。对于PD-L1表达指数大

Sci Rep:CT扫描图像检测肺结节的有效可靠框架

实证结果表明该技术对于降低假阳性率非常有效。敏感率高达令人惊叹的97.45%。

徐松涛教授:EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位

EGFR-TKI已成为晚期EGFR突变阳性非小细胞肺癌(NSCLC)的标准治疗,显着地延长了患者的总生存时间。近年来随着ADJUVANT等研究结果的公布,EGFR-TKI开始应用于术后辅助治疗,在新辅助治疗中的研究也正在开展。

肺癌治疗新发现!microRNA可作为逆转和预防肺癌耐药性的潜在靶点!

近日,来自以色列医学癌症中心的研究团队进行的一项新研究发现,一种特殊突变基因的小片段——调节基因表达的非编码基因材料——微小RNA介导了肺癌靶向药物治疗的耐药性。这表明,microRNA可以作为逆转和预防肺癌耐药性的潜在靶点。这是继极光激酶后肺癌靶向治疗的又一大突破。相关论文发表在《nature》子刊《Nature Metabolism》上。肺癌是全球癌症致死的主要原因之一,某些肺癌的特征在于名为

Chest:建立风险预测模型以估算考虑活检肺结节的恶性概率

这项研究开发了8个模型,用于帮助表征被临床医生认为高危推荐活检的PNs。

又一城市正式执行4+7带量采购 肺癌患者得享百元救命药

4月1日,广州市正式执行4+7带量采购。此次4+7带量采购政策惠及的疾病领域包括肿瘤、精神类疾病、心血管病、癫痫、哮喘、腹泻等,这些患者将感受到政策带来的重大利好。中山大学附属肿瘤医院张力教授表示:“4+7带量采购政策给我市癌症患者带来了福音。此前虽然已有很多抗癌药进入我市医保目录,但依旧有很多患者有经济负担。而4+7带量采购政策的落实使这些药品再次降价,百姓的报销政策也有了改善。以此次4+7集中